Glimepirid Ved doser, som langt overstiger terapeutiske doser til mennesker, er der præklinisk fundet virkninger, som anses for at have ringe klinisk relevans eller som skyldes den farmakodynamiske virkning (hypoglykæmi) af produktet.
Glimepiride Preclinical effects were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use or were caused by the pharmacodynamic effect (hypoglycaemia) of the substance.